Publications by authors named "Eric Barkley"
Among adults at risk for severe coronavirus disease 2019 (COVID-19), the lowest hospitalization rate was among those who received nirmatrelvir-ritonavir after 3 or more messenger RNA vaccine doses (adjusted hazard ratio, 0.22; 95% confidence interval, .19-.
View Article and Find Full Text PDFArticle Synopsis
- - Over 30,000 cases of mpox were reported in the U.S. by March 2023, primarily affecting transgender individuals and men who have sex with men, with the JYNNEOS vaccine available for preventing the infection.
- - A case-control study analyzed the effectiveness of the JYNNEOS vaccine using data from a large electronic health record database, comparing vaccinated patients who contracted mpox to those who did not.
- - Results showed that full vaccination with JYNNEOS had an estimated effectiveness of 66%, while partial vaccination had an effectiveness of 35.8%, indicating that vaccinated individuals were less likely to contract mpox compared to unvaccinated individuals.
Nirmatrelvir-ritonavir (Paxlovid), an oral antiviral treatment, is authorized for adults with mild-to-moderate COVID-19 who are at increased risk for progression to severe illness. However, real-world evidence on the benefit of Paxlovid, according to vaccination status, age group, and underlying health conditions, is limited. To examine the benefit of Paxlovid in adults aged ≥18 years in the United States, a large electronic health record (EHR) data set (Cosmos) was analyzed to assess the association between receiving a prescription for Paxlovid and hospitalization with a COVID-19 diagnosis in the ensuing 30 days.
View Article and Find Full Text PDFPrevious infection with SARS-CoV-2, the virus that causes COVID-19, has been estimated to confer up to 90% protection against reinfection, although this protection was lower against the Omicron variant compared with that against other SARS-CoV-2 variants (1-3). A test-negative design was used to estimate effectiveness of COVID-19 mRNA vaccines in preventing subsequent COVID-19-associated hospitalization among adults aged ≥18 years with a previous positive nucleic acid amplification test (NAAT) or diagnosis of COVID-19. The analysis used data from Cosmos, an electronic health record (EHR)-aggregated data set (4), and compared vaccination status of 3,761 case-patients (positive NAAT result associated with hospitalization) with 7,522 matched control-patients (negative NAAT result).
View Article and Find Full Text PDF